Heatmap analysis demonstrated widespread correlations between CD58 and these immunomodulators in nearly all cancers, except for CHOL, ESCA, diffuse large B-cell lymphoma (DLBC), and uterine carcinosarcoma (UCS) (Figures 2A–E). This evidence concerns the gene CD58 and diffuse large B-cell lymphoma.